Trials / Completed
CompletedNCT01782833
Pletaal SR Post Marketing Observational Study
A Prospective, Post Marketing Observational Study to Evaluate the Safety of Pletaal® SR Capsule
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,635 (actual)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.
Detailed description
This study will be conducted in a prospective, single-arm, multi-center format. As this study is observational in nature, the patient's follow-up is not prescriptive in nature and must be left up to the judgment of the physician (investigator), within the period of observation set forth in the protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | This is Non-interventional study |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-12-31
- Completion
- 2014-12-31
- First posted
- 2013-02-04
- Last updated
- 2019-03-01
- Results posted
- 2018-09-21
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01782833. Inclusion in this directory is not an endorsement.